argenx NV ADR
Prices are adjusted according to historical splits.
Vitals
- Today's Low:
- $369.53
- Today's High:
- $374.46
- Open Price:
- $371.93
- 52W Low:
- $267.345
- 52W High:
- $407.93
- Prev. Close:
- $376.47
- Volume:
- 179276
Company Statistics
- Market Cap.:
- $18.72 billion
- Book Value:
- 53.945
- Revenue TTM:
- $285.68 million
- Operating Margin TTM:
- -296.82%
- Gross Profit TTM:
- $-52254000
- Profit Margin:
- 0%
- Return on Assets TTM:
- -16.49%
- Return on Equity TTM:
- -30.64%
Company Profile
argenx NV ADR had its IPO on 2017-05-18 under the ticker symbol ARGX.
The company operates in the Healthcare sector and Biotechnology industry. argenx NV ADR has a staff strength of 650 employees.
Stock update
Shares of argenx NV ADR opened at $371.93 at the start of the last trading session i.e. 2023-03-30.
The stocks traded within a range of $369.53 - $374.46, and closed at $369.83.
This is a -1.76% slip from the previous day's closing price.
A total volume of 179,276 shares were traded at the close of the day’s session.
In the last one week, shares of argenx NV ADR have increased by +3.64%.
argenx NV ADR's Key Ratios
argenx NV ADR has a market cap of $18.72 billion, indicating a price to book ratio of 7.2361 and a price to sales ratio of 78.2208.
In the last 12-months argenx NV ADR’s revenue was $285.68 million with a gross profit of $-52254000 and an EBITDA of $-845139968. The EBITDA ratio measures argenx NV ADR's overall financial performance and is widely used to measure its profitability.
In the trailing 12-month period, argenx NV ADR’s operating margin was -296.82% while its return on assets stood at -16.49% with a return of equity of -30.64%.
In Q4, argenx NV ADR’s quarterly earnings growth was a positive 0% while revenue growth was a positive 440.7%.
argenx NV ADR’s PE and PEG Ratio
- Forward PE
- 0
- Trailing PE
- 0
- PEG
- 0
Its diluted EPS in the last 12-months stands at $-15.93 per share while it has a forward price to earnings multiple of 0 and a PEG multiple of 0. A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.
The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into argenx NV ADR’s profitability.
argenx NV ADR stock is trading at a EV to sales ratio of 72.3023 and a EV to EBITDA ratio of -21.2464. Its price to sales ratio in the trailing 12-months stood at 78.2208.
argenx NV ADR stock pays annual dividends of $0 per share, indicating a yield of 0% and a payout ratio of 0%.
Balance sheet and cash flow metrics
- Total Assets
- $0
- Total Liabilities
- $0
- Operating Cash Flow
- $0
- Capital Expenditure
- $0
- Dividend Payout Ratio
- 0%
argenx NV ADR ended 2023 with $0 in total assets and $0 in total liabilities. Its intangible assets were valued at $0 while shareholder equity stood at $0.
argenx NV ADR ended 2023 with $0 in deferred long-term liabilities, $0 in other current liabilities, in common stock, $0 in retained earnings and $0 in goodwill. Its cash balance stood at $0 and cash and short-term investments were $0. The company’s total short-term debt was $0 while long-term debt stood at $0.
argenx NV ADR’s total current assets stands at $0 while long-term investments were $0 and short-term investments were $0. Its net receivables were $0 compared to accounts payable of $0 and inventory worth $0.
In 2023, argenx NV ADR's operating cash flow was $0 while its capital expenditure stood at $0.
Comparatively, argenx NV ADR paid $0 in dividends in 2023.
Other key metrics
- Current Trading Price
- $369.83
- 52-Week High
- $407.93
- 52-Week Low
- $267.345
- Analyst Target Price
- $452.58
argenx NV ADR stock is currently trading at $369.83 per share. It touched a 52-week high of $407.93 and a 52-week low of $407.93. Analysts tracking the stock have a 12-month average target price of $452.58.
Its 50-day moving average was $366.65 and 200-day moving average was $370.72 The short ratio stood at 4.38 indicating a short percent outstanding of 0%.
Around 0.2% of the company’s stock are held by insiders while 5575.2% are held by institutions.
Frequently Asked Questions About argenx NV ADR
Similar Industry Stocks (Biotechnology)
Most Active
Top Gainers
Top Losers
About
argenx SE, a biotechnology company, focuses on developing various therapies for the treatment of autoimmune diseases in the United States, the Netherlands, Belgium, Japan, Switzerland, Germany and France. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, and chronic inflammatory demyelinating polyneuropathy in Phase III clinical trials; bullous pemphigoid and idiopathic inflammatory myopathy in Phase II/III clinical trials; and ENHANZE SC in Pre-clinical study. The company is also developing immunology innovation programs, including cusatuzumab for hematological cancer, as well as high risk MDS; ARGX-119, an antibody that targets muscle-specific tyrosine kinase stage; ARGX-117 for severe autoimmune indications; ARGX-118 for airway inflammation; and ARGX-120 to treat autoimmune diseases. In addition, its partnered product candidates include ARGX-115 for the treatment of cancer; ARGX-112 to treat interleukin-22 receptor; and ARGX-114, an antibody directed against the MET receptor. The company has strategic partnership with AbbVie S.À.R.L., Zai Lab Limited, and LEO Pharma A/S; and collaboration and license agreement with Genor Biopharma Co. Ltd, Université Catholique de Louvain, Sopartec S.A., NYU Langone Health, Leiden University Medical Center, AgomAb Therapeutics NV, Broteio Pharma B.V., University of Texas, BioWa, Inc., Cilag GmbH International, Staten Biotechnology B.V., and Shire International GmbH. argenx SE was incorporated in 2008 and is based in Breda, the Netherlands.